Wedbush analyst David Nierengarten maintained a Buy rating on Ikena Oncology (IKNA – Research Report) today and set a price target of $8.00. The company’s shares closed yesterday at $1.32.
According to TipRanks, Nierengarten is a 5-star analyst with an average return of 11.3% and a 43.24% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Fate Therapeutics, Oric Pharmaceuticals, and Xencor.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ikena Oncology with a $9.50 average price target.
The company has a one-year high of $7.38 and a one-year low of $1.02. Currently, Ikena Oncology has an average volume of 397.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ikena Oncology (IKNA) Company Description:
Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme Kynase; discovery-stage molecules targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.
